Research programme: protein therapeutics - Inpharmatica/Merck Serono

Drug Profile

Research programme: protein therapeutics - Inpharmatica/Merck Serono

Alternative Names: Protein therapeutics research programme - Inpharmatica/Merck Serono

Latest Information Update: 13 Mar 2008

Price : $50

At a glance

  • Originator Galapagos NV; Merck Serono
  • Class Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 08 Jan 2007 Serono is now called Merck Serono
  • 05 Jan 2007 Serono has been acquired by Merck KGaA
  • 09 Sep 2003 Inpharmatica and Serono have extended their research collaboration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top